Genscript Biotech (1548.HK) Aandeel Koers
Genscript Biotech Koers
De omzet is de afgelopen 13 jaar met 25,0% per jaar gegroeid tot 959,53 Miljoen USD. De winst per aandeel is de afgelopen 11 jaar met 41,7% per jaar gegroeid. De nettowinstmarge van Genscript Biotech ligt op -55,5% en is ten opzichte van -68,1% enkele jaren eerder gestegen. Genscript Biotech biedt momenteel een dividendrendement van circa 0,29%. De uitkeringsratio ligt rond 10% van de winst. Analisten hanteren een mediaan koersdoel van 2,53 USD — dat impliceert 39,9% onder de huidige koers. Van de 16 analisten geven 15 het aandeel een koopadvies — per saldo een Kopen-consensus.
Genscript Biotech aandeelkoers
Deze data ophalen via de Eulerpool API
100.000 requests/maand gratis · geen creditcard
Genscript Biotech bedrijfsmodel & aandelenanalyse
Veelgestelde vragen over Genscript Biotech
The business model of Genscript Biotech Corp focuses on providing integrated solutions for life sciences research and drug discovery. The company offers a comprehensive range of products and services, including gene synthesis, protein expression, antibody development, and molecular diagnostics. Genscript Biotech Corp aims to accelerate biological research and development by providing high-quality and cost-effective solutions to scientists worldwide. Through its innovative technologies and expertise, the company has gained a strong reputation in the biotech industry. Genscript Biotech Corp continually strives to enhance its capabilities and expand its product portfolio to meet the evolving needs of the scientific community.
Genscript Biotech Corp is primarily active in the biotechnology industry.
The main competitors of Genscript Biotech Corp in the market are Thermo Fisher Scientific Inc., Eurofins Scientific SE, and Sartorius AG.
Genscript Biotech Corp is a leading biotechnology company with a rich history and background. Established in 2002, the company specializes in providing high-quality services and products in the field of life sciences research. Genscript is dedicated to enabling advancements in scientific discoveries and breakthroughs through its expertise in gene synthesis, custom protein production, antibody development, and many other gene-related services. With its state-of-the-art facilities and a global customer base, Genscript has become a trusted partner for researchers and pharmaceutical companies worldwide. The company's commitment to innovation and excellence has helped propel it to the forefront of the biotech industry, making Genscript Biotech Corp a reliable choice for investors seeking opportunities in this dynamic sector.
Genscript Biotech Corp has achieved several significant milestones. As a leading biotechnology company, Genscript has made remarkable strides in the field. Notably, the company successfully completed the genome synthesis of the E. coli bacterium in 2010, which was a groundbreaking achievement. In 2015, Genscript became the first Chinese biotech firm to be listed on the Hong Kong Stock Exchange, marking a significant milestone for the company. Moreover, Genscript has continuously expanded its portfolio of services and products, catering to various research areas and providing innovative solutions to the scientific community. With such achievements, Genscript Biotech Corp stands as a prominent player in the biotech industry.
Genscript Biotech Corp is primarily present in several countries and regions across the globe. The company has a strong foothold in China, where its headquarters are located. Additionally, Genscript Biotech Corp has a significant presence in the United States, with offices and operations spread across various states. The company has also established a strong international presence, with operations and collaborations in Europe, Asia, and other regions worldwide. With its global reach, Genscript Biotech Corp continues to expand its presence and deliver innovative solutions in the field of biotechnology.
Genscript Biotech Corp represents values of innovation, collaboration, and commitment to scientific advancement. With a strong corporate philosophy centered around providing quality products and services, Genscript strives to enhance the understanding and application of biotechnology worldwide. The company is dedicated to delivering cutting-edge research tools, custom solutions, and high-quality services to enable scientists and researchers in various fields. Genscript Biotech Corp aims to foster a culture of excellence, integrity, and customer-centricity, positioning itself as a global leader in the biotech industry.
Analisten hanteren momenteel een gemiddeld koersdoel van 2,68 USD voor het aandeel Genscript Biotech (mediaan: 2,53 USD), oftewel -36,4 % ten opzichte van de laatste koers. De consensus is gebaseerd op 16 analistenratings.
16 analisten beoordelen het aandeel Genscript Biotech momenteel: 15 adviseren kopen, 1 houden en 0 verkopen. Voor 2026 verwachten analisten dat Genscript Biotech een omzet van 887,77 Miljoen USD en winst per aandeel van 0,01 USD behaalt.
Omgezet tegen de huidige wisselkoers noteert het aandeel Genscript Biotech op 3,78 EUR (4,21 USD).
Het aandeel Genscript Biotech (1548.HK) is genoteerd aan 4 beurzen, waaronder: Hongkong (HKEX) (1548.HK), Frankfurt (G51.F), München (G51.MU).
GenScript Biotech Corp is a leading company in the biotech industry that specializes in the development and manufacture of high-quality biological products and services. The company offers a wide range of products and services, including DNA synthesis, protein production, antibody production, cell line development, and diagnostic tools. The company's divisions include proprietary products, manufacturing, and CRO (Contract Research Organization). Proprietary products contribute a large portion of the company's revenue and include various products such as CRISPR/Cas9 kits, DNA sequencing, protein analysis, and antibody services. GenScript Biotech's manufacturing business model is highly tailored to customer needs. It is based on critical procedures that incorporate proven expertise and patented technologies. The model includes a targeted approach to developing the necessary production processes, quality controls at every step of the manufacturing process, and support throughout the customer's entire lifecycle. An essential goal of the company is to support customers in every phase of the manufacturing process to ensure smooth and successful production. The Contract Research Organization (CRO) division of GenScript Biotech focuses on supporting customers in early stages of biological research or clinical trials. Through partnerships with the company, customers are supported through services such as protein engineering, cell line development, cell therapy, in vivo services, and pharmaceutical development. The company also offers a variety of diagnostic solutions and laboratory services. Examples include the development of cellular assays, reagent manufacturing, and DNA sequencing services. Overall, GenScript Biotech Corp is strongly focused on providing rapid and flexible service to its customers by offering a wide range of biopharmaceuticals, diagnostic tools, and laboratory services. The company has a global presence with offices in China, the USA, Europe, Japan, and Singapore. As a company that prioritizes innovation and quality, GenScript Biotech holds a strong position in the biotechnology market. With its various divisions and high-quality offering of products and services, the company provides its customers with a valuable partner to achieve their goals in biotechnology.
De verwachte omzet van Genscript Biotech bedraagt 887,77 Miljoen USD. Deze cijfers zijn gebaseerd op huidige financiële gegevens en weerspiegelen de bedrijfsresultaten van het bedrijf.
De verwachte winst van Genscript Biotech bedraagt 13,75 Miljoen USD. De nettowinst weerspiegelt de rentabiliteit van het bedrijf na aftrek van alle kosten.
De koers-winstverhouding (P/E) van Genscript Biotech bedraagt momenteel 681,81. De P/E-ratio vergelijkt de huidige aandeelkoers met de winst per aandeel en helpt beleggers de waardering van het Genscript Biotech-aandeel in te schatten.
De koers-omzetverhouding (P/S) van Genscript Biotech bedraagt momenteel 10,56. De P/S-ratio vergelijkt de marktkapitalisatie met de jaarlijkse opbrengsten en dient als waarderingsmaatstaf voor het Genscript Biotech-aandeel.
De Eulerpool Kwaliteitsscore voor Genscript Biotech is 5/10.
De ISIN van Genscript Biotech is KYG3825B1059. De ISIN (International Securities Identification Number) is een wereldwijd unieke identificatie voor wertpapieren.
De WKN van Genscript Biotech is A2ACSB. De WKN (Wertpapierkennnummer) is een zescijferig Duits identificatienummer voor wertpapieren.
Het tickersymbool van Genscript Biotech is 1548.HK. Onder dit beurstickersymbool wordt het Genscript Biotech-aandeel op de beurs verhandeld.
Genscript Biotech aandeel
Genscript Biotech Peer Group
Genscript Biotech Ticker
Genscript Biotech FIGI
Alle fundamentals en diepgaande analyse van Genscript Biotech
Onze aandelenanalyse van het Genscript Biotech-aandeel omvat belangrijke financiële kerncijfers zoals de omzet, de winst, de P/E-ratio, de P/S-ratio, de EBIT, evenals informatie over het dividend. Daarnaast bekijken we aspecten zoals aandelen, marktkapitalisatie, schulden, eigen vermogen en verplichtingen van Genscript Biotech. Als u meer gedetailleerde informatie zoekt over deze onderwerpen, bieden we op onze subpagina's uitgebreide analyses: